New protein injection shows promise in early Alzheimer's trial

NCT ID NCT06489015

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-phase study tests a lab-made protein (recombinant human serum albumin) in 30 people with mild to moderate Alzheimer's. Participants receive one of three doses to check safety and any effect on thinking skills. The goal is to see if this treatment can help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE(AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Medical College & Affiliated Hospital Of Jiujiang University

    Jiujiang, Jiangxi, 332000, China

  • Luoyang Third People's Hospital

    Luoyang, Henan, 471002, China

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, 200000, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450000, China

  • Wuhan Union Hospital of China

    Wuhan, Hubei, 430000, China